At this year's European Society of Medical Oncology (ESMO) Congress — held September 27 to October 1, 2019, in Barcelona, Spain — investigators reported the latest findings in cancer research. Here, NEJM Journal Watch Oncology and Hematology Editor-in-Chief William J. Gradishar reviews key presentations of new breast cancer therapies. All abstracts can be accessed via ESMO 2019 Oncology Meeting Resources.
Abemaciclib plus Trastuzumab and Fulvestrant for HR+, HER2+ Advanced Breast Cancer
Tolaney and colleagues presented results from the randomized, open-label, phase II monarcHER study, in which 237 postmenopausal patients with hormone receptor–positive (HR+), human epidermal growth factor 2–positive (HER2+) advanced breast cancer were randomiz…
Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)